[go: up one dir, main page]

WO2009116074A3 - Substituted benzimidazoles as cannabinoid modulator - Google Patents

Substituted benzimidazoles as cannabinoid modulator Download PDF

Info

Publication number
WO2009116074A3
WO2009116074A3 PCT/IN2009/000099 IN2009000099W WO2009116074A3 WO 2009116074 A3 WO2009116074 A3 WO 2009116074A3 IN 2009000099 W IN2009000099 W IN 2009000099W WO 2009116074 A3 WO2009116074 A3 WO 2009116074A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
substituted benzimidazoles
regioisomers
stereoisomers
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2009/000099
Other languages
French (fr)
Other versions
WO2009116074A2 (en
Inventor
Harikishore Pingali
Mukul R. Jain
Pankaj M. Makadia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Lifesciences Ltd
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of WO2009116074A2 publication Critical patent/WO2009116074A2/en
Publication of WO2009116074A3 publication Critical patent/WO2009116074A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel compounds of general formula (I), their stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. The present invention also relates to a process of preparing novel compounds of general formula (I), their stereoisomers, regioisomers, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.
PCT/IN2009/000099 2008-02-13 2009-02-12 Substituted benzimidazoles as cannabinoid modulator Ceased WO2009116074A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN313/MUM/2008 2008-02-13
IN313MU2008 2008-02-13

Publications (2)

Publication Number Publication Date
WO2009116074A2 WO2009116074A2 (en) 2009-09-24
WO2009116074A3 true WO2009116074A3 (en) 2009-11-12

Family

ID=41057444

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000099 Ceased WO2009116074A2 (en) 2008-02-13 2009-02-12 Substituted benzimidazoles as cannabinoid modulator

Country Status (1)

Country Link
WO (1) WO2009116074A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
MX339243B (en) 2011-02-03 2016-05-18 Vtv Therapeutics Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof.
JP6688735B2 (en) 2014-02-11 2020-04-28 バイエル・ファルマ・アクティエンゲゼルシャフト Benzimidazol-2-amines as mIDH1 inhibitors
EP3105209B1 (en) 2014-02-11 2019-08-21 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
WO2016062677A1 (en) * 2014-10-23 2016-04-28 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
US10137110B2 (en) 2014-10-23 2018-11-27 Bayer Pharma Aktiengesellschaft 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
CN107810176B (en) 2015-06-08 2020-10-16 德国癌症研究公共权益基金会 N-menthylbenzimidazoles as mIDH1 inhibitors
WO2017009325A1 (en) 2015-07-16 2017-01-19 Bayer Pharma Aktiengesellschaft 5-hydroxyalkylbenzimidazoles as midh1 inhibitors
US10683292B2 (en) * 2016-07-25 2020-06-16 Nerviano Medical Sciences S.R.L. Purine and 3-deazapurine analogues as choline kinase inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085866A1 (en) * 2001-04-20 2002-10-31 Astrazeneca Ab Novel compounds
WO2008153701A1 (en) * 2007-05-24 2008-12-18 Schering Corporation Compounds for inhibiting ksp kinesin activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085866A1 (en) * 2001-04-20 2002-10-31 Astrazeneca Ab Novel compounds
WO2008153701A1 (en) * 2007-05-24 2008-12-18 Schering Corporation Compounds for inhibiting ksp kinesin activity

Also Published As

Publication number Publication date
WO2009116074A2 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
WO2009116074A3 (en) Substituted benzimidazoles as cannabinoid modulator
MX2010012529A (en) Phenyl and benzodioxinyl substituted indazoles derivatives.
PH12015501199B1 (en) Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
WO2010150281A3 (en) Novel azabicyclohexanes
MY145812A (en) Substituted imidazoles
WO2009093269A9 (en) Novel heterocyclic compounds
UA101835C2 (en) Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
WO2009125434A3 (en) Oxime derivatives, process for their preparation, pharmaceutical composition containing the same and medicinal use thereof
TNSN07006A1 (en) Novel heterocyclic compounds
PH12012501153A1 (en) Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
WO2007017728A3 (en) Novel heterocyclic compounds
WO2008059513A3 (en) Compounds suitable as modulators of hdl
MX2010001512A (en) Novel preparation process.
MX2011008126A (en) Substituted indole compounds as bradykinin receptor 1 modulators.
WO2010122580A3 (en) Piperidine derivatives as inhibitors of renin
WO2009053999A3 (en) Sulfoximine derivatives as factor xa inhibitors
ZA200804858B (en) Sulfoximine derivatives as p38 map kinase inhibitors
WO2008062424A3 (en) Substituted 4,5-dihydro-1h-pyrazole derivatives as cannabinoid modulators
WO2006109146A3 (en) Novel heterocyclic derivatives
WO2007007161A3 (en) Novel bio-active derivatives
UA92736C2 (en) 1h-imidazole derivatives as cannabinoid cb2 receptor modulators
MY142535A (en) Tricyclic pyrazole derivatives as cannabinoid receptor modulators
WO2006126074A3 (en) Heterocyclic derivatives
WO2011016050A3 (en) Novel compounds as modulators of glucocorticoid receptors
UA84594C2 (en) 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives as cb1 antagonists

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09723491

Country of ref document: EP

Kind code of ref document: A2